Somatropin (Growth Hormone)



ATC CODE

  • H01AC01

INDICATIONS AND NEMLC RECOMMENDATIONS

INDICATIONS AND NEMLC RECOMMENDATIONS 1

INDICATION

  • Turner’s syndrome.

NEMLC RECOMMENDATION

  • Not Approved

REVIEW INDICATORS

  • Improved cost-effectiveness.

DATE RATIFIED

  • 20 September 2007



INDICATIONS AND NEMLC RECOMMENDATIONS 2

INDICATION

  • Prader Willi syndrome.

NEMLC RECOMMENDATION

  • Not Approved

REVIEW INDICATORS

  • Price.

DATE RATIFIED

  • 20 September 2007



INDICATIONS AND NEMLC RECOMMENDATIONS 3

INDICATION

  • Intrauterine growth failure.

NEMLC RECOMMENDATION

  • Not Approved

REVIEW INDICATORS

  • Price.

DATE RATIFIED

  • 20 September 2007



INDICATIONS AND NEMLC RECOMMENDATIONS 4

INDICATION

  • Idiopathic short stature.

NEMLC RECOMMENDATION

  • Not Approved

REVIEW INDICATORS

  • Improved cost-effectiveness.

DATE RATIFIED

  • 20 September 2007



INDICATIONS AND NEMLC RECOMMENDATIONS 5

INDICATION

  • Chronic renal insufficiency.

NEMLC RECOMMENDATION

  • Not Approved

REVIEW INDICATORS

  • Evidence of benefit.

DATE RATIFIED

  • 20 September 2007



INDICATIONS AND NEMLC RECOMMENDATIONS 6

INDICATION

  • Growth hormone deficiency.

NEMLC RECOMMENDATION

  • Approved
    Approved for confirmed growth hormone deficiency for use by endocrinologists only.
    Rationale:
    • The condition is a well-defined deficiency state that can be managed and monitored.
    • Number of patients requiring treatment is small.

REVIEW INDICATORS

  • New evidence on quality of life assessment in local and specific populations.

DATE RATIFIED

  • 24 July 2008